Phase 1B study of PTC299 in relapsed/refractory acute leukemias
MD Anderson Study Status
This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Leukemia, Myeloid, Acute, AML
For general questions about clinical trials: